Elekta Ab Class B · OMXSTO:EKTA_B
Elekta Ab Class B — Investor Day (January 2015)
34 slides from Elekta Ab Class B's investor day presentation, Jan 22, 2015
Slide 1: Elekta R&D Update
Elekta R&D Update 22 January 2015, Utrecht 1
Slide 2: Elekta R&D Update - 22 January 2015, Utrecht
Elekta R&D Update - 22 January 2015, Utrecht 11.00 R&D Update Niklas Savander President and CEO 11.15 Atlantic Positioning Dee Mathieson, SVP Oncology Business Line Management 11.30 Atlantic Update Kevin Brown Head of Scientific and Medical Affairs 11.40 Q&A All speakers 12.00 Informal Q&A Professor
Slide 3: Elekta R&D update
Elekta R&D update Niklas Savander President & CEO Utrecht, 22 January 2015 3
Slide 4: Strategic choices
Strategic choices • Emerging markets • Product innovation • Software 4
Slide 5: Strategic agenda for growth
Strategic agenda for growth Innovation Leadership Grow the Pie Customers Commercial Lifecycle Transformation Management Patients 5
Slide 6: Innovation is in our DNA
Innovation is in our DNA 1949 1985 2006 2013 Stereotaxy First digital Integrated oncology Electronic brachytherapy Leksell Stereotactic controlled software solutions for skin cancer frame linac Esteya® The Future in Radiation Therapy Elekta Atlantic 1968 2003 2008 Radiosurgery Image Guided VMAT Leks
Slide 7: R&D key programs and spend
R&D key programs and spend Fiscal year 2014/15 Main Elekta R&D programs: Brachytherapy • Atlantic Neuroscience 9% • Information Guided Cancer Care 14% • Next generation Gamma Knife 42% Oncology • Vision 2020 for Brachytherapy Software 35% 7
Slide 8: R&D investments for future growth
R&D investments for future growth SEK M % of net sales 1 200 12% • 2013/14: step change in R&D 1 000 10% investments 800 8% − MRI-guided radiation therapy system 600 6% • Expected to grow more in line 400 4% with sales going forward 200 2% • Return to R&D level of 0 0% 08/09 09/10 10/11 11/12 12/13
Slide 9: Atlantic launch and price
Atlantic launch and price Planning Ambition Consortium orders – research systems 8 Regulatory approvals - CE Mark, 510(k) During 2017 Launch and taking commercial orders 2017 First deliveries of commercial orders 2018 Total orders and deliveries during ramp 75 up phase (until 2019) Average price ± 4
Slide 10: Market expectations
Market expectations • Most top RT centers in the world are interested • Over 100 hospitals have asked for bunker specifications • Atlantic to be expected standard of care within 10 years • High potential to Grow the Pie 10
Slide 11: Collaboration enables Elekta innovation success
Collaboration enables Elekta innovation success • Unique 12 year research collaboration with UMCU regarding Atlantic • Philips as MRI technology partner • Strong engagement with members of Atlantic consortium 11
Slide 12: G ELEKTA
G ELEKTA
Slide 13: Atlantic positioning
Atlantic positioning Dee Mathieson Senior Vice President, Oncology Business Line Management Utrecht, 22 January 2015 13
Slide 14: The Future of Cancer Care Atlantic
The Future of Cancer Care Atlantic Tomorrow’s RT: Today’s RT: Increased Accuracy • Better outcomes AND Precision IGRT with VMAT is • Lower costs Standard of Care Real-Time Adaption • Potential for new (motion, shape, biology) indications 14
Slide 15: Pioneering Partnership International
Pioneering Partnership International Visionary To discover and enhance Leading new technologies that focus on improving and prolonging peoples lives. 15
Slide 16: Introduction & Ramp-up
Introduction & Ramp-up >75 orders 2017 2018 2019 8 Research Systems 1st Commercial orders 1st Commercial deliveries subject to RA clearance in markets 16
Slide 17: Milestones to market
Milestones to market 2018 2017 Clinical Pilots Installation Non-Clinical Pilots Installation 1st installations of the Development Started with Research Consortium Commercial Release Imminent 1st Commercial orders subject to RA clearance in markets Proof of Concept 2012 FAST TRACK 2009 Red journal ar
Slide 18: Strong interest and potential
Strong interest and potential • Most of the leading RT centres worldwide have expressed interest • The early adopters are willing to invest up front and partner with us to demonstrate the Clinical & Economic value of Atlantic • Key opinion leaders share a consensus that Atlantic will deliver superio
Slide 19: Atlantic sets the bar
Atlantic sets the bar MRg RT Space Through the Elekta-Philips partnership, Atlantic +++* will deliver the full potential of MRgRT that High-Field Magnet requires best of both worlds: ATLANTIC • Image quality & performance of high-field MRI • Beam accuracy of modern delivery technology Image Quality
Slide 20: Radiation Therapy Landscape
Radiation Therapy Landscape Large breadth Ability to place dose accurately of Applications (Mainstream) Excellent Good ATLANTIC LINAC With VMAT* Proton System with & Cone-Beam CT* Cone-Beam CT* Limited breadth of Applications (Niche) Moderate Proton System with Portal Imaging Ability to shape Modera
Slide 21: Alignment with Strategic Agenda
Alignment with Strategic Agenda Cancer Care Spending USD 188 bn Halo Effect Chemotherapy Grow the Pie Radiation therapy Innovation leadership Surgery Stem Cell Immunotherapy transplant 21
Slide 22: G ELEKTA
G ELEKTA
Slide 23: Atlantic Update
Atlantic Update Kevin Brown Head of Scientific and Medical Affairs Utrecht, 22 January 2015 23
Slide 24: Progress in MRI-guided radiation therapy
Progress in MRI-guided radiation therapy Previously we have shown the experimental First generation high field MRI-guided system at Utrecht, the Netherlands radiation therapy system is now under test 24
Slide 25: Progress in MRI-guided radiation therapy
Progress in MRI-guided radiation therapy Demonstrated Demonstrated • 1.5 T MRI imaging quality for both 3D • 1.5 T MRI imaging quality for both 3D and 2D Cine and 2D Cine • Image quality not affected by: • Image quality not affected by: − Radiation − Radiation − Presence of Linac Gantry at any angle
Slide 26: First generation high field MRI-guided radiation therapy system
First generation high field MRI-guided radiation therapy system Example volunteer images High resolution (0.7mm x 0.7mm x 1mm), 3D acquisition with exquisite image quality in all planes High frame rate, multi-planar acquisition for motion monitoring 26 Images courtesy of Philips
Slide 27: Elekta Atlantic consortium established
Elekta Atlantic consortium established The consortium aims to: • Demonstrate improved patient outcomes for existing radiation therapy indications • Extend radiation therapy with new treatment techniques and be able to treat more indications Each consortium member will have a MR linac for: • Identify
Slide 28: Leading consortium members
Leading consortium members ICR – The Royal Marsden Froedtert and Medical College of Wisconsin UMC Utrecht The Christie AVL-NKI MD Anderson Cancer Center - Houston Sunnybrook - Toronto 7 sites have signed up About 100 people spread all over the world Including the Elekta and Philips project teams we
Slide 29: Position uncertainty
Relative strengths of MRI and CBCT High Pancreas Kidney Isolated Lung Cervix Position uncertainty Rectum Target motion/ Breast Central Lung Spine (cord) Prostate Cranium Brain Low High Tissue contrast Low
Slide 30: Image and detect the target in real time
Image and detect the target in real time • Localization results for Kidney • Alternating axial, coronal and sagittal slices • Acquired and processed in 200 ms
Slide 31: ICR demonstrate feasibility of dynamic target tracking
ICR demonstrate feasibility of dynamic target tracking using Elekta Agility as a test platform • Fast leaf motion including integrated Dynamic Leaf guides • Fast dynamic orthogonal jaws − Seamlessly manages target motion orthogonal to leaf travel • Exceptionally Low latency − Less than 100 ms • Exce
Slide 32: Atlantic room is comparable to a Linac room
Atlantic room is comparable to a Linac room Radiation shielded room RF shielded room
Slide 33: Recent progress
Recent progress • Testing at UMCU continues − Successfully reproduced all the proof of concept tests on commercial grade system − All performance specs have been met or exceeded • Feasibility of following moving targets with the MLC in real time demonstrated − Done without any surrogates and combine
Slide 34: G ELEKTA
G ELEKTA